---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-004726"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2025-04-11T23:59:59+00:00"
generated_at: "2026-05-23T16:12:26.674971+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics awards $237,500 retention bonus to CFO/Interim CEO Kenyon

## Summary
- Cash retention bonus of $237,500 approved by Compensation Committee on April 9, 2025.
- Bonus payable December 31, 2025, contingent on Kenyon's continuous employment through that date.
- Kenyon declined option to receive stock options in lieu of cash; no election made.
- Upon a qualifying termination before Dec 31, 2025, bonus accelerated subject to release of claims.
- Retention bonus letter filed as Exhibit 10.1 with the 8-K.

## SEC filing metadata
- accession: 0001558370-25-004726
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2025-04-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000155837025004726/0001558370-25-004726-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000155837025004726/otlk-20250409x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-004726
- JSON: https://secwatch.observer/filing/0001558370-25-004726.json
- Plain text: https://secwatch.observer/filing/0001558370-25-004726.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.